FULC Q3 2022 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-76.0% YoY

Gross Profit

-$14M-1198.9% margin

Operating Income

-$24M-2058.7% margin

Net Income

-$24M-2006.6% margin

EPS (Diluted)

$-0.52

QoQ Revenue Growth

-37.1%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$248M

Total Liabilities

$26M

Stockholders' Equity

$221M

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$5M	-76.0%
Gross Profit	-$14M	-$12M	-16.8%
Operating Income	-$24M	-$21M	-17.3%
Net Income	-$24M	-$21M	-14.6%